Nutex Health, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1290956,
    "name": "Nutex Health, Inc.",
    "stock_name": "Nutex Health, Inc.",
    "full_name": "Nutex Health, Inc.",
    "name_url": "stocks-analysis/nutex-health-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "156.79",
    "chg": 27.02,
    "chgp": "20.82%",
    "dir": 1,
    "prev_price": "129.77",
    "mcapval": "463.35",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US67079U1088",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "580.66 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nutex-health-inc-1290956-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Nutex Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nutex-health-inc-overvalued-or-undervalued-3638011",
        "imagepath": "",
        "date": "2025-10-21 12:13:26",
        "description": "As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 2.82, indicating strong earnings relative to enterprise value. Additionally, the company boasts an impressive ROCE of 128.63% and ROE of 76.34%, reflecting exceptional profitability.\n\nIn comparison to its peers, Nutex Health, Inc. has a more favorable EV to EBITDA ratio than Fulgent Genetics, Inc., which is at -8.0743, and Talkspace, Inc., which is at -344.3683. This suggests that Nutex is performing better in terms of operational efficiency and value creation. Over the past year, Nutex Health has delivered a remarkable stock return of 326.80%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion..."
      },
      {
        "title": "Is Nutex Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nutex-health-inc-overvalued-or-undervalued-3634883",
        "imagepath": "",
        "date": "2025-10-20 12:30:43",
        "description": "As of 17 October 2025, the valuation grade for Nutex Health, Inc. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison to peers, Nutex Health's EV to EBITDA ratio is significantly lower than Talkspace, Inc. at -344.3683 and Fulgent Genetics, Inc. at -8.0743, suggesting a more favorable valuation relative to its industry.\n\nNutex Health has demonstrated remarkable stock performance, with a year-to-date return of 199.26% compared to the S&P 500's 13.30%, and an astounding 3-year return of 10,965.93% versus the S&P 500's 81.19%. This performance reinforces the narrative that the stock is undervalued in the current market context...."
      },
      {
        "title": "Is Nutex Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nutex-health-inc-overvalued-or-undervalued-3632420",
        "imagepath": "",
        "date": "2025-10-19 12:07:55",
        "description": "As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a low P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison, Fulgent Genetics, Inc. has a significantly negative P/E ratio of -21.28, while Talkspace, Inc. is considered expensive with a P/E of 156.07, highlighting Nutex's relative value.\n\nNutex Health has demonstrated exceptional stock performance, with a year-to-date return of 199.26%, vastly outperforming the S&P 500's 13.30% during the same period. This strong return reinforces the notion that Nutex Health is undervalued in the current market context...."
      },
      {
        "title": "Is Nutex Health, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nutex-health-inc-technically-bullish-or-bearish-3548461",
        "imagepath": "",
        "date": "2025-09-20 20:18:11",
        "description": "As of 9 June 2025, the technical trend for Nutex Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting the overall mildly bullish stance. However, the weekly Bollinger Bands and KST are bearish, and the Dow Theory shows a mildly bullish weekly but mildly bearish monthly outlook. \n\nIn terms of performance, Nutex Health has significantly outperformed the S&P 500 year-to-date with a return of 193.34% compared to the S&P 500's 12.22%, and over the past year, it has returned 273.93% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is Nutex Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nutex-health-inc-overvalued-or-undervalued-3544479",
        "imagepath": "",
        "date": "2025-09-20 18:47:27",
        "description": "As of 7 July 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its perceived value. The company appears to be undervalued based on its key ratios, including a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. \n\nWhen compared to peers, Nutex Health's valuation metrics stand out; for example, Fulgent Genetics, Inc. has a P/E ratio of -21.28, and Talkspace, Inc. is considered expensive with a P/E of 156.07. Despite some recent volatility, Nutex Health has significantly outperformed the S&P 500 over the year, with a return of 273.93% compared to the S&P 500's 17.14%, reinforcing its attractive valuation story...."
      },
      {
        "title": "Nutex Health Achieves 279.75% Growth, Establishing It as a Multibagger in Biotechnology Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nutex-health-achieves-27975-growth-establishing-it-as-a-multibagger-in-biotechnology-sector-3520044",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NutexHealthInc_multibagger_3520044.png",
        "date": "2025-09-16 15:21:29",
        "description": "Nutex Health, Inc. has recently undergone a revision in its score, reflecting its impressive performance in the Pharmaceuticals & Biotechnology sector. The company has achieved significant growth over the past year, outpacing the S&P 500, while maintaining strong financial health and operational efficiency, attracting increased institutional interest."
      }
    ],
    "total": 11,
    "sid": "1290956",
    "stock_news_url": "https://www.marketsmojo.com/news/nutex-health-inc-1290956"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Nutex Health, Inc. overvalued or undervalued?

2025-10-21 12:13:26

As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 2.82, indicating strong earnings relative to enterprise value. Additionally, the company boasts an impressive ROCE of 128.63% and ROE of 76.34%, reflecting exceptional profitability. In comparison to its peers, Nutex Health, Inc. has a more favorable EV to EBITDA ratio than Fulgent Genetics, Inc., which is at -8.0743, and Talkspace, Inc., which is at -344.3683. This suggests that Nutex is performing better in terms of operational efficiency and value creation. Over the past year, Nutex Health has delivered a remarkable stock return of 326.80%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion...

Is Nutex Health, Inc. overvalued or undervalued?

2025-10-20 12:30:43

As of 17 October 2025, the valuation grade for Nutex Health, Inc. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison to peers, Nutex Health's EV to EBITDA ratio is significantly lower than Talkspace, Inc. at -344.3683 and Fulgent Genetics, Inc. at -8.0743, suggesting a more favorable valuation relative to its industry. Nutex Health has demonstrated remarkable stock performance, with a year-to-date return of 199.26% compared to the S&P 500's 13.30%, and an astounding 3-year return of 10,965.93% versus the S&P 500's 81.19%. This performance reinforces the narrative that the stock is undervalued in the current market context....

Is Nutex Health, Inc. overvalued or undervalued?

2025-10-19 12:07:55

As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a low P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison, Fulgent Genetics, Inc. has a significantly negative P/E ratio of -21.28, while Talkspace, Inc. is considered expensive with a P/E of 156.07, highlighting Nutex's relative value. Nutex Health has demonstrated exceptional stock performance, with a year-to-date return of 199.26%, vastly outperforming the S&P 500's 13.30% during the same period. This strong return reinforces the notion that Nutex Health is undervalued in the current market context....

Is Nutex Health, Inc. technically bullish or bearish?

2025-09-20 20:18:11

As of 9 June 2025, the technical trend for Nutex Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting the overall mildly bullish stance. However, the weekly Bollinger Bands and KST are bearish, and the Dow Theory shows a mildly bullish weekly but mildly bearish monthly outlook. In terms of performance, Nutex Health has significantly outperformed the S&P 500 year-to-date with a return of 193.34% compared to the S&P 500's 12.22%, and over the past year, it has returned 273.93% versus the S&P 500's 17.14%....

Is Nutex Health, Inc. overvalued or undervalued?

2025-09-20 18:47:27

As of 7 July 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its perceived value. The company appears to be undervalued based on its key ratios, including a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. When compared to peers, Nutex Health's valuation metrics stand out; for example, Fulgent Genetics, Inc. has a P/E ratio of -21.28, and Talkspace, Inc. is considered expensive with a P/E of 156.07. Despite some recent volatility, Nutex Health has significantly outperformed the S&P 500 over the year, with a return of 273.93% compared to the S&P 500's 17.14%, reinforcing its attractive valuation story....

Nutex Health Achieves 279.75% Growth, Establishing It as a Multibagger in Biotechnology Sector

2025-09-16 15:21:29

Nutex Health, Inc. has recently undergone a revision in its score, reflecting its impressive performance in the Pharmaceuticals & Biotechnology sector. The company has achieved significant growth over the past year, outpacing the S&P 500, while maintaining strong financial health and operational efficiency, attracting increased institutional interest.

View All News